Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Residual endotoxin induces primary graft dysfunction through ischemia/reperfusion-primed alveolar macrophages
Mahzad Akbarpour, … , G.R. Scott Budinger, Ankit Bharat
Mahzad Akbarpour, … , G.R. Scott Budinger, Ankit Bharat
Published May 19, 2020
Citation Information: J Clin Invest. 2020;130(8):4456-4469. https://doi.org/10.1172/JCI135838.
View: Text | PDF
Research Article Immunology Transplantation

Residual endotoxin induces primary graft dysfunction through ischemia/reperfusion-primed alveolar macrophages

  • Text
  • PDF
Abstract

Despite the widespread use of antibiotics, bacterial pneumonias in donors strongly predispose to the fatal syndrome of primary graft dysfunction (PGD) following lung transplantation. We report that bacterial endotoxin persists in human donor lungs after pathogen is cleared with antibiotics and is associated with neutrophil infiltration and PGD. In mouse models, depletion of tissue-resident alveolar macrophages (TRAMs) attenuated neutrophil recruitment in response to endotoxin as shown by compartmental staining and intravital imaging. Bone marrow chimeric mice revealed that neutrophils were recruited by TRAM through activation of TLR4 in a MyD88-dependent manner. Intriguingly, low levels of endotoxin, insufficient to cause donor lung injury, promoted TRAM-dependent production of CXCL2, increased neutrophil recruitment, and led to PGD, which was independent of donor NCMs. Reactive oxygen species (ROS) increased in human donor lungs starting from the warm-ischemia phase and were associated with increased transcription and translocation to the plasma membrane of TLR4 in donor TRAMs. Consistently, scavenging ROS or inhibiting their production to prevent TLR4 transcription/translocation or blockade of TLR4 or coreceptor CD14 on donor TRAMs prevented neutrophil recruitment in response to endotoxin and ameliorated PGD. Our studies demonstrate that residual endotoxin after successful treatment of donor bacterial pneumonia promotes PGD through ischemia/reperfusion-primed donor TRAMs.

Authors

Mahzad Akbarpour, Emilia Lecuona, Stephen F. Chiu, Qiang Wu, Melissa Querrey, Ramiro Fernandez, Félix L. Núñez-Santana, Haiying Sun, Sowmya Ravi, Chitaru Kurihara, James M. Walter, Nikita Joshi, Ziyou Ren, Scott C. Roberts, Alan Hauser, Daniel Kreisel, Wenjun Li, Navdeep S. Chandel, Alexander V. Misharin, Thalachallour Mohanakumar, G.R. Scott Budinger, Ankit Bharat

×

Figure 4

Influx of recipient neutrophils into the allograft containing LPS is abrogated by depletion of donor TRAMs and is CXCL2 dependent.

Options: View larger image (or click on image) Download as PowerPoint
Influx of recipient neutrophils into the allograft containing LPS is abr...
(A) Diagram depicting experiment shown in B. WT C57BL/6 mice received BALB/c allogeneic donor lungs containing low-dose LPS (0.5 μg/g BW) injected i.t., insufficient to cause native lung injury. To deplete NCMs, donors were treated with i.v. Clo-lip before i.t. LPS. To deplete both donor monocytes and donor TRAMs, we treated the donors with i.v. Clo-lip and i.t. Clo-lip, respectively, before i.t. LPS. Next, we used Nr4a1–/– donor lungs containing low-dose LPS and transplanted them into WT recipients after depletion of TRAMs using i.t. Clo-lip, or using PBS-lip as control. Last, to determine whether CXCL2 secretion by donor TRAMs led to neutrophil recruitment, we treated recipients of Nr4a1–/– donor lungs containing low-dose LPS with anti-CXCL2 antibodies at the time of transplantation. Additionally, we transplanted Nr4a1–/– donor lungs containing low-dose LPS into Cxcr2–/– recipients and determined neutrophil infiltration at 24 hours.(B) Quantification of neutrophil infiltration into lungs after these treatments was performed using flow cytometry (n = 4–5). (C) CXCL2 chemokine levels in BALF of recipient mice after receiving low-dose LPS-treated Nr4a1–/– donor lungs compared with PBS-treated Nr4a1–/– donor lungs (n = 5). (D) TRAMs were isolated from endotoxin-negative and endotoxin-positive human donor lungs at 120 minutes after reperfusion and analyzed for CXCL2 transcription (n = 4). All graphs show mean ± SD. Graph in B was analyzed by 1-way ANOVA followed by Tukey’s post hoc test. Graphs in C and D were analyzed by unpaired t test. ***P < 0.01; ****P < 0.0001. CT, control.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts